{"title":"Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.","authors":"Gregory F Guzauskas, Marc Salzberg, Bruce Cm Wang","doi":"10.2217/cns-2018-0010","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients.</p><p><strong>Methods: </strong>We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years.</p><p><strong>Results & conclusion: </strong>Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost-effectiveness of TTFields.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/cns-2018-0010","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2018-0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/8/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 16
Abstract
Aim: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients.
Methods: We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years.
Results & conclusion: Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost-effectiveness of TTFields.
目的:评估新诊断的胶质母细胞瘤患者在替莫唑胺维持治疗(TMZ)的基础上增加肿瘤治疗领域(TTFields)的平均终生生存获益，这是肿瘤学健康经济评估的重要组成部分。方法:我们将EF-14试验数据与胶质母细胞瘤流行病学数据相结合。该模型提供了一种基于证据的方法来估计5年仍存活的EF-14试验患者的物质数量。结果与结论:TTFields和TMZ联合治疗的患者平均生存期增加1.8年(TTFields/TMZ: 4.2 vs TMZ单独治疗:2.4)。开始TTFields治疗后第2年存活的患者存活至第10年的概率为20.7%。本文提出的结果为未来评估TTFields的增量成本效益提供了所需的增量生存效益。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
